A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Kronos is cutting 83% of its workforce, while Idorsia is considering cutting as many as 270 jobs. Elsewhere, PTC disclosed ...